Categories: NewsPharmaceutical

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its first quarter 2023 financial results after the market closes on Monday, May 8, 2023. The Company will also host a conference call and webcast on May 9, 2023, at 8:30 am ET, to discuss the Company’s first quarter 2023 financial results and to provide a corporate update.

The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

The live and archived webcast of the call will be available on the Quoin Pharmaceuticals website under the Investors section: https://investors.quoinpharma.com/news-and-events/events-and-presentations

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:
Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341

Staff

Recent Posts

Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments

R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development…

4 minutes ago

Google Cloud and Philips Collaborate to Drive Consumer Marketing Innovation and Transform Digital Asset Management with AI

Google Cloud helps streamline marketing processes, enhancing brand consistency and reducing operational costs AMSTERDAM and…

4 minutes ago

Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities

ZEIST, Netherlands, May 14, 2025 /PRNewswire/ -- Julius Clinical, a leading full-service Contract Research Organization (CRO)…

4 minutes ago

SolarEast Launches Global R290 Heat Pump System to Advance Climate Goals and Energy Efficiency

BEIJING, May 14, 2025 /PRNewswire/ -- SolarEast, a leading manufacturer of air-to-water heat pumps, has…

4 minutes ago

Avance Clinical Honored with Frost & Sullivan’s 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services

This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in…

5 minutes ago

Weiser Memorial Hospital Notifies Individuals of Data Security Incident

WEISER, Idaho, May 13, 2025 /PRNewswire/ -- Weiser Memorial Hospital ("WMH") is providing notice of…

6 hours ago